CI vs. WST: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CI and WST, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CI | WST |
|---|---|---|
| Company Name | The Cigna Group | West Pharmaceutical Services, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Life Sciences Tools & Services |
| Market Capitalization | 83.01 billion USD | 19.60 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 31, 1982 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CI and WST by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CI | WST |
|---|---|---|
| 5-Day Price Return | 8.50% | 4.70% |
| 13-Week Price Return | -2.74% | 22.63% |
| 26-Week Price Return | -5.47% | 21.74% |
| 52-Week Price Return | -8.72% | -9.09% |
| Month-to-Date Return | 7.89% | 3.90% |
| Year-to-Date Return | 12.62% | -16.79% |
| 10-Day Avg. Volume | 1.64M | 0.66M |
| 3-Month Avg. Volume | 1.77M | 0.68M |
| 3-Month Volatility | 29.75% | 54.14% |
| Beta | 0.29 | 1.15 |
Profitability
Return on Equity (TTM)
CI
12.27%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
CI’s Return on Equity of 12.27% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
WST
17.66%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, WST’s Return on Equity of 17.66% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
CI
1.92%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
CI’s Net Profit Margin of 1.92% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
WST
16.48%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
WST’s Net Profit Margin of 16.48% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
CI
3.41%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
CI’s Operating Profit Margin of 3.41% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
WST
19.65%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
WST’s Operating Profit Margin of 19.65% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | CI | WST |
|---|---|---|
| Return on Equity (TTM) | 12.27% | 17.66% |
| Return on Assets (TTM) | 3.26% | 13.10% |
| Net Profit Margin (TTM) | 1.92% | 16.48% |
| Operating Profit Margin (TTM) | 3.41% | 19.65% |
| Gross Profit Margin (TTM) | 9.86% | 35.27% |
Financial Strength
Current Ratio (MRQ)
CI
0.79
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
CI’s Current Ratio of 0.79 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
WST
2.78
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
WST’s Current Ratio of 2.78 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CI
0.77
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
CI’s Debt-to-Equity Ratio of 0.77 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
WST
0.07
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
Falling into the lower quartile for the Life Sciences Tools & Services industry, WST’s Debt-to-Equity Ratio of 0.07 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
CI
2.32
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
CI’s Interest Coverage Ratio of 2.32 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
WST
130.12
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
With an Interest Coverage Ratio of 130.12, WST demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | CI | WST |
|---|---|---|
| Current Ratio (MRQ) | 0.79 | 2.78 |
| Quick Ratio (MRQ) | 0.68 | 2.08 |
| Debt-to-Equity Ratio (MRQ) | 0.77 | 0.07 |
| Interest Coverage Ratio (TTM) | 2.32 | 130.12 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CI
1.96%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Yield of 1.96% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
WST
0.30%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
WST’s Dividend Yield of 0.30% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
CI
31.63%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Payout Ratio of 31.63% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
WST
12.32%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
WST’s Dividend Payout Ratio of 12.32% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | CI | WST |
|---|---|---|
| Dividend Yield (TTM) | 1.96% | 0.30% |
| Dividend Payout Ratio (TTM) | 31.63% | 12.32% |
Valuation
Price-to-Earnings Ratio (TTM)
CI
16.17
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
CI’s P/E Ratio of 16.17 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
WST
40.47
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
WST’s P/E Ratio of 40.47 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CI
0.31
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
CI’s P/S Ratio of 0.31 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
WST
6.67
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
WST’s P/S Ratio of 6.67 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
CI
2.20
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
CI’s P/B Ratio of 2.20 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
WST
5.37
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
WST’s P/B Ratio of 5.37 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | CI | WST |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.17 | 40.47 |
| Price-to-Sales Ratio (TTM) | 0.31 | 6.67 |
| Price-to-Book Ratio (MRQ) | 2.20 | 5.37 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.54 | 57.38 |